Get the Stockscreener App
200.29
2.13%
4.17
After Hours:
200.90
0.61
+0.30%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $200.29, with a volume of 787.49K.
It is up +2.13% in the last 24 hours and up +4.95% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$196.12
Open:
$197.41
24h Volume:
787.49K
Relative Volume:
0.90
Market Cap:
$22.17B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
22.09
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
+2.77%
1M Performance:
+4.95%
6M Performance:
+9.74%
1Y Performance:
+15.34%
1-Day Range:
$197.31
$201.54
1-Week Range:
$191.01
$201.99
52-Week Range:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
200.29 | 21.71B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
[144] QUEST DIAGNOSTICS INC SEC Filing - Stock Titan
Quest Diagnostics Insider Sold Shares Worth $1,941,400, According to a Recent SEC Filing - marketscreener.com
Insider Sell: J. Davis Sells 10,000 Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Quest Diagnostics CEO sells $1.94 million in company stock By Investing.com - Investing.com Australia
Quest Diagnostics CEO sells $1.94 million in company stock - Investing.com
Quest Diagnostics (DGX) CEO sells 10,000 shares in Rule 10b5-1 trade - Stock Titan
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
Affiliate sale notice — DGX (DGX) to sell 10,000 shares - Stock Titan
DGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year? - Yahoo Finance
Quest Diagnostics Stock: Analyst Estimates & Ratings - Yahoo Finance
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting - Investing.com India
Quest Diagnostics 8-K SEC Filing May 2026: Shareholder Vote Results and Company Information - Minichart
Quest Diagnostics (DGX) Announces Results of 2026 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com South Africa
Quest Diagnostics (DGX) director granted 1,142 restricted stock units in Form 4 filing - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 RSUs - Stock Titan
Quest Diagnostics (DGX) director receives 1,142-share restricted stock unit grant - Stock Titan
Quest Diagnostics (DGX) director gets 1,142-share restricted stock unit award - Stock Titan
Director Tracey Doi of Quest Diagnostics (DGX) receives 1,142-share equity award - Stock Titan
Director at Quest Diagnostics (DGX) awarded 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 stock units - Stock Titan
Quest Diagnostics (DGX) director receives 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (DGX) receives 1,142 share units - Stock Titan
Quest Diagnostics (NYSE: DGX) details 2026 shareholder votes on board, pay and auditor - Stock Titan
Why is Quest Diagnostics (DGX) down 5% since last earnings report? - MSN
Why Is Quest Diagnostics (DGX) Down 5% Since Last Earnings Report? - Yahoo Finance
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Keeps Quarterly Dividend at $0.86 a Share, Payable July 22 to Holders of Record July 8 - marketscreener.com
Quest Diagnostics Declares Quarterly Cash Dividend - Barchart.com
Guardant Health’s Shield Blood-Based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics - Nevada Business Magazine
Is This the Right Time to Hold DGX Stock in Your Portfolio? - TradingView
$0.86 a share: Quest Diagnostics dividend hits investors in July - Stock Titan
Quest Diagnostics Incorporated announces Quarterly dividend, payable on July 22, 2026 - marketscreener.com
Baird Adjusts Price Target on Quest Diagnostics to $232 From $229, Maintains Neutral Rating - Moomoo
Quest Diagnostics (NYSE:DGX): A Solid Dividend Play Backed by Strong Profitability and Financial Health - ChartMill
International Assets Investment Management LLC Purchases New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
Q2 EPS Estimates for Quest Diagnostics Cut by Zacks Research - MarketBeat
173,262 Shares in Quest Diagnostics Incorporated $DGX Bought by Conning Inc. - MarketBeat
How The Investment Narrative For Quest Diagnostics (DGX) Is Shifting With New Valuation Work - Yahoo Finance
Quest Diagnostics Incorporated (NYSE:DGX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Global HPV Testing and Pap Test Market is Expected to Showcase a Significant Growth at a CAGR of ~7% by 2034 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics Incorporated $DGX Shares Acquired by Ethic Inc. - MarketBeat
Truist Financial Corp Cuts Stock Holdings in Quest Diagnostics Incorporated $DGX - MarketBeat
Swedbank AB Increases Stake in Quest Diagnostics Incorporated $DGX - MarketBeat
Generali Asset Management SPA SGR Purchases 8,924 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):